Compound Reference

BPC-157

Body Protection Compound 157 · a synthetic pentadecapeptide (15 amino acids)

Healing & tissue-repair research Evidence: preclinical + early human pilots RUO · not FDA-approved · WADA-prohibited

Research Use Only. BPC-157 is not approved by the FDA or EMA for any use, and is not a medicine. Nothing on this page is medical advice or an instruction to use, prepare, or administer anything. It is an educational summary of what the published research does and does not show.

What it is

BPC-157 is a synthetic 15-amino-acid peptide whose sequence corresponds to a fragment of a larger protein ("Body Protection Compound") isolated from human gastric juice. Unlike many peptides, it is reported to be notably stable in gastric acid, which is why it appears in research in both injectable and oral forms.¹ It is one of the most heavily studied peptides in tissue-, tendon-, ligament-, muscle-, bone-, and gut-healing research models — almost entirely in animals.

Proposed mechanism of action

There is no single agreed mechanism; the literature describes several proposed pathways, observed mainly in rodent and cell models:

Angiogenesis (new blood-vessel formation). The most-cited pathway: BPC-157 appears to promote endothelial growth via the VEGFR2 → Akt → eNOS signaling axis, supporting blood supply to healing tissue.²
Nitric-oxide (NO) system modulation. Effects on NO synthesis/release are repeatedly reported and may underlie both vascular and cytoprotective findings.¹
Growth-factor / receptor interplay. In tendon-fibroblast studies it is reported to upregulate the growth-hormone receptor and influence FAK–paxillin and EGR-1 pathways tied to cell migration and matrix remodeling.²
Gut–brain axis effects. Animal work reports interactions with dopaminergic and serotonergic systems — interesting, but early and not established in humans.¹

How to read this: "proposed mechanism" means a pathway supported by preclinical data — not a proven mechanism in people. BPC-157 does not act on one clean receptor the way, say, a GLP-1 agonist does; its effects are described as broadly cytoprotective and pleiotropic.

Pharmacology & pharmacokinetics

Chemical class	Synthetic pentadecapeptide (15 aa); partial sequence of gastric "Body Protection Compound"
Molecular weight	≈ 1419 Da
Reported stability	Stable in human gastric juice (unusual for a peptide) — hence oral research forms exist¹
Half-life	Not well characterized in humans; native peptide clearance is thought to be rapid. Robust human PK data do not exist.
Routes in research	Injectable and oral used in preclinical studies; topical/ophthalmic explored in animals

State of the evidence — read this before anything else

This is the single most important section, and it is where the internet gets BPC-157 most wrong.

Animal evidence: extensive and often striking across many injury models.
Human evidence: very limited — on the order of a few small published pilot studies, with small numbers of participants.³
Phase III / placebo-controlled RCTs: none. As of this writing there are zero large randomized controlled trials establishing efficacy or safety in humans.³

A structural reason underlies this gap: as a short, naturally-derived sequence, BPC-157 is difficult to patent, which removes the commercial incentive that funds large human trials. Impressive animal data plus little human data is exactly the profile that fuels overstated online claims.

Regulatory & sport status

FDA/EMA: not approved for any indication; sold only as a research chemical (RUO).
Compounding: BPC-157 was flagged by the FDA in category 2 of its bulk-substances review, meaning significant safety questions were raised about compounding it.
WADA: prohibited at all times under class S0 (non-approved substances) — relevant for any tested athlete.

Reconstitution (reference only)

For lab handling reference only — not a preparation instruction. Research literature typically describes lyophilized BPC-157 reconstituted with bacteriostatic or sterile water to a working concentration, then refrigerated. See our reconstitution calculator for the arithmetic of concentration and draw volume. This site does not provide dosing or administration guidance.

Reading a BPC-157 COA

Because BPC-157 is RUO and unregulated, the Certificate of Analysis matters more, not less. Confirm identity by mass spectrometry against ≈1419 Da, purity by HPLC (aim ≥98% with one clean peak), a matching batch number, and a recent third-party test date. See how to read a COA.

Open questions

Does the striking animal healing data translate to humans at all, and at what exposure?
What is its real human pharmacokinetics and long-term safety profile?
Which of the proposed mechanisms actually drive the observed effects?

References

Background, indications, efficacy and safety of BPC-157 and TB-500 (2025). globalrph.com
Peptide Therapeutics 2.0 — open-access review of peptide drug mechanisms & development. PMC7287585
Injectable peptide therapy in orthopaedics/sports medicine — evidence primer. PubMed 41476424

Explore the full library & 75-compound reference →

For educational and research purposes only. This content is not medical advice. Compounds referenced are research use only and not intended to diagnose, treat, cure, or prevent any disease. Free Peptide University does not sell compounds.